A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma

Trial Profile

A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs CD40L GVAX (Primary) ; Aldesleukin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Prednisone; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
    • 09 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
    • 16 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top